NEJM 22 Feb 2007
26 Feb, 07 | by BMJ Group
Tidings of Seretide to send sales soaring. This study, funded by GlaxoSmithKline (and hence in part by you, dear taxpayer), finds “significant benefits
Categories
- Carbon (4)
- Careering Around (8)
- Comment (306)
- Developments to bmj.com (3)
- Editors at large (37)
- From the other side (10)
- Guest bloggers (23)
- Junior doctors (23)
- Making a Difference (3)
- MTAS (36)
- Quality forum (3)
- Richard Lehman's weekly review of medical journals (256)
- Students (4)
Browse our archives